All In Biotech

Drug Trial Radar · NCT06116617

A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jan 23, 2024

Primary completion

Dec 9, 2024

Study completion Apr 30, 2025

Sponsor

Lead sponsor
Sirius Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary aim of this study is to evaluate safety and tolerability data when SRSD107 is administered as single SC injections to healthy participants. This information, along with PK/PD data, will help establish the appropriate doses and dosing regimen for future studies in patients.

Conditions

  • Thrombosis

Interventions

  • SRSD107Drug

    SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA).

  • PlaceboDrug

    Sodium chloride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of adverse events (AEs)Time frame: up to 168 days post last dose
  2. Proportion of Serious Adverse Events (SAEs)Time frame: up to 168 days post last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical Research

    Perth, Other (Non U.s.), Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.